Compare THH & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THH | BFRI |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 12.2M |
| IPO Year | 2025 | 2021 |
| Metric | THH | BFRI |
|---|---|---|
| Price | $1.32 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 15.0K | ★ 168.1K |
| Earning Date | 11-21-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,705,000.00 |
| Revenue This Year | N/A | $10.65 |
| Revenue Next Year | N/A | $15.88 |
| P/E Ratio | $305.05 | ★ N/A |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $0.19 | $0.57 |
| 52 Week High | $56.26 | $1.66 |
| Indicator | THH | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 39.08 |
| Support Level | $0.27 | $0.77 |
| Resistance Level | $1.50 | $0.96 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 22.92 | 23.31 |
Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.